Drugs / Random Donor Plasma
last change May 2020 re-read 2 minutes ago

Random Donor Plasma

Developed for
COVID-19

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04346446 Comparator Apr → May 2020 COVID-19 Institute of Liver and Biliary Sciences, India Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Random Donor Plasma ClinicalTrials.gov intervention name — accepted as the source's own label NCT04346446
Route Other “Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement” NCT04346446